Core Viewpoint - GRAIL, Inc. and Quest Diagnostics have launched a program to enhance access to GRAIL's Galleri multi-cancer early detection test for healthcare providers in the U.S., streamlining the ordering process and improving patient access to the test [1][2][3] Group 1: Collaboration and Integration - The integration of the Galleri test into Quest's connectivity system allows providers to order the test electronically, enhancing efficiency in the ordering process [1][3] - Quest Diagnostics has approximately 7,400 patient access points nationwide, enabling patients to access the Galleri test without needing to bring a test kit to their appointment [2][3] Group 2: Cancer Detection Capabilities - The Galleri test detects DNA fragments shed by cancers, acting as a "fingerprint" to identify multiple deadly cancers before symptoms appear, including those without recommended screening tests [3][4][7] - The test is recommended for adults aged 50 or older and is intended to be used alongside standard cancer screenings [4][10] Group 3: Sensitivity and Effectiveness - The Galleri test shows high sensitivity for various cancers, including pancreas cancer (83.7% overall), esophagus cancer (85.0% overall), ovary cancer (83.1% overall), and liver/bile duct cancer (93.5% overall) [9]
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System